Mapp wins fast-track status for Ebola drug; Roche builds a tower of Basel;

@FierceBiotech: RegenX IPO raises $138M, renewing hopes for a big Q4 biotech run. Article | Follow @FierceBiotech

@JohnCFierce: Allergan and Richter win FDA approval for a once-rejected schizophrenia pill. News | Follow @JohnCFierce

> Mapp Biopharmaceutical secured the FDA's fast-track status for ZMapp, its in-development treatment for Ebola virus. News

> Aduro Biotech ($ADRO) has leased a 56,000-square-foot space in Berkeley to house its R&D efforts as it moves forward with a pipeline of immuno-oncology treatments. Story

> Roche ($RHHBY) has constructed a 41-story skyscraper in its native Basel, a move that "can be seen as a defiant reaction to the arrival of others moving into a space Roche has dominated for the last 15 years," an analyst told Reuters. More

Medical Device News

@FierceMedDev: ICYMI yesterday: U.K. scientists develop ultrasonic device to better clean medical instruments. Article | Follow @FierceMedDev

@EmilyWFierce: Jaychem Industries is feeling the burn from an FDA warning letter over its GolfersSkin Sunscreen. FiercePharmaManufacturing story | Follow @EmilyWFierce

> Penumbra goes public in upsized $120M deal, med tech's largest IPO of 2015. Story

> Upstart Establishment gets $20M+ to bring safer breast implants with nanotech, RFID tracking to U.S. Article

> FDA cautions against improperly cleaned bronchoscope devices. More

Pharma News

@FiercePharma: India's Sun Pharma makes $48M purchase of eyecare firm InSite Vision. FiercePharmaAsia item | Follow @FiercePharma

@EricPFierce: Ireland pharma biz going to the dogs, so to speak. Nextvet picks up biologics plant there. FiercePharmaManufacturing item | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Perrigo officially rejects Mylan's 'insulting,' 'ego'-driven buyout offer. Item | Follow @CarlyHFierce

> Perrigo CEO has slammed Mylan for months--but he owns its shares. More

> FDA asks Pfizer for Zoloft label update highlighting birth defect risks. Story

> Allergan and Richter's antipsychotic gets FDA OK but faces stiff competition. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.